Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

This open-label Phase I trial (n=15) will assess the feasibility and safety of a single 25 mg dose of psilocybin combined with psychotherapy in women aged 18–45 with chronic pelvic pain (CPP) who have not responded to at least one conventional treatment.

The study, conducted by Oregon Health and Science University and led by Dr. Lynne Shinto, aims to explore a novel approach to managing CPP by targeting the psychological and neurological underpinnings of pain perception. CPP, often associated with central sensitisation (a condition where the central nervous system becomes hypersensitive to pain), affects around 15% of women in the U.S. and is commonly linked to conditions such as endometriosis, fibromyalgia, and irritable bowel syndrome.

Participants will receive preparatory psychotherapy prior to dosing and follow-up integration sessions after the psilocybin session. Researchers hope to determine whether participants can safely complete the full course of treatment and evaluate acceptability and early effects on pain, mood, and quality of life. The trial, supported in part by the Circle of Giving Foundation, is expected to run from August 2025 to July 2026.

Topic Pain
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Oregon Health & Science University
Psychedelic research is underway at the Oregon Health and Science University. It is likely more research will emerge given the state recently legalized psilocybin.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.